摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

thiazolo[2',3′:2,3]imidazo[4,5-c]isoquinolin-5(6H)-one

中文名称
——
中文别名
——
英文名称
thiazolo[2',3′:2,3]imidazo[4,5-c]isoquinolin-5(6H)-one
英文别名
thiazolo[2',1':2,3]imidazo[4,5-c]isoquinolin-5(6H)-one;thiazolo[2',3':2,3]imidazo[4,5-c]isoquinolin-5(6H)-one;14-Thia-9,11,16-triazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,12,15-hexaen-8-one
thiazolo[2',3′:2,3]imidazo[4,5-c]isoquinolin-5(6H)-one化学式
CAS
——
化学式
C12H7N3OS
mdl
——
分子量
241.273
InChiKey
UYYSRPUUYBAAMJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    17
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    74.6
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    thiazolo[2',3′:2,3]imidazo[4,5-c]isoquinolin-5(6H)-one4-硝基苯基硼酸 在 copper diacetate 吡啶三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 72.0h, 以21%的产率得到6-(4-nitro-phenyl)-thiazolo[2',3':2,3]imidazo[4,5-c]isoquinolin-5(6H)-one
    参考文献:
    名称:
    WO2007/113290
    摘要:
    公开号:
  • 作为产物:
    描述:
    在 tetrafluorohydroboric acid 作用下, 以 正丁醇 为溶剂, 反应 0.33h, 生成 thiazolo[2',3′:2,3]imidazo[4,5-c]isoquinolin-5(6H)-one
    参考文献:
    名称:
    Towards molecular diversity: dealkylation of tert-butyl amine in Ugi-type multicomponent reaction product establishes tert-butyl isocyanide as a useful convertible isonitrile
    摘要:
    随着一种新型微波辅助单锅联产去叔丁基化的开发,在Ugi型多组分反应生成物中,叔丁基异氰酸酯作为一种有用的可转化异腈首次被探讨,从而获得了制药上重要的多环氮融合咪唑杂环的分子多样性。
    DOI:
    10.1039/c0ob00022a
点击查看最新优质反应信息

文献信息

  • A chemoselective Ugi-type reaction in water using TMSCN as a functional isonitrile equivalent: generation of heteroaromatic molecular diversity
    作者:Sankar Kumar Guchhait、Vikas Chaudhary、Chetna Madaan
    DOI:10.1039/c2ob26733k
    日期:——
    KF-mediated nucleophilic activation of TMSCN as a functional isonitrile equivalent establishes an efficient and chemoselective Ugi-type multicomponent reaction of a heterocyclic amidine and aldehyde with TMSCN in water. In this approach, the use of isocyanide is circumvented, known competing reactions are virtually eliminated, pure products are obtained by a non-chromatographic method, and therapeutically relevant and diverse N-fused 3-aminoimidazoles can be prepared from a wide variety of aldehydes and heterocyclic amidines. This reaction coupling with cascade cyclization provides various privileged tetracyclic heteroaromatic scaffolds.
    KF催化的TMSCN亲核活化作为功能性异腈等价物,建立了羟基胺和醛与TMSCN在中进行的高效且化学选择性的Ugi类型多组分反应。在这种方法中,避免了异氰酸酯的使用,已知的竞争反应几乎被消除,纯产品通过非色谱法获得,并且可从多种醛和杂环胺制备出具有治疗相关性和多样性的N-融合3-咪唑。该反应结合级联环化提供了多种特权的四环杂芳烃骨架。
  • HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES
    申请人:Kesteleyn Bart Rudolf Romanie
    公开号:US20090170855A1
    公开(公告)日:2009-07-02
    HIV inhibitory compounds of formula: salts, hydrates, solvates, N-oxides, or stereoisomers thereof, wherein A forms pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, and thiadiazole; R 1 is halo, cyano, nitro, C 1-6 alkyl, polyhaloC 1-6 alkyl, —C 1-6 alkyl-OR 4 , —C(═O)—R 5 , —C(═O)—OR 4 , —C(═O)—NR 6 R 7 , —OR 4 , —O—C(═O)—C 1-6 alkyl, —O—C 1-6 alkyl-OR 4 , —O—C 1-6 alkyl-NR 6 R 7 , —O—C 1-6 alkyl-O—C(═O)—C 1-6 alkyl, —O—C 1-6 alkyl-C(═O)—OR 4 , —O—C 1-6 alkyl-C(═O)—NR 6 R 7 , —NR 6 R 7 , —NR 8 —C(═O)—R 5 , —NR 8 —C(═O)—OR 4 , —NR 8 —C(═O)—NR 6 R 7 , —NR 8 —C(═O)—C 1-6 alkyl-C(═O)—OR 4 , —NR 8 —C 1-6 alkyl-OR 4 , —NR 8 —C 1-6 alkyl-NR 6 R 7 , —NR 8 —C 1-6 alkyl-imidazolyl, —NR 8 —SO 2 R 9 , —N═CH—NR 6 R 7 , —NH—C(═NH)—NH 2 , —SO 2 NR 6 R 7 , and —O—PO(OR 8 ) 2 ; D forms pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophene, thiazole, and isothiazole; R 2 is C 1 -C 6 alkyl, polyhaloC 1 -C 6 alkyl, halo, cyano, —COOR 4 , —OR 4 , and —NR 6 R 7 ; R 3 is phenyl, pyridyl, pyrimidinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, quinoline, imidazopyrimidinyl, pyrazolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl; which may optionally be substituted; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.
    公式为:其中A为吡啶嘧啶吡嗪吡嗪二氮杂环、三嗪、咪唑吡唑、三唑、四唑噁唑异噁唑噻唑异噻唑噻唑;R1为卤素、基、硝基、C1-6烷基、多卤C1-6烷基、—C1-6烷基-OR4、—C(═O)—R5、—C(═O)—OR4、—C(═O)—NR6R7、—OR4、—O—C(═O)—C1-6烷基、—O—C1-6烷基-OR4、—O—C1-6烷基-NR6R7、—O—C1-6烷基-O—C(═O)—C1-6烷基、—O—C1-6烷基-C(═O)—OR4、—O—C1-6烷基-C(═O)—NR6R7、—NR6R7、—NR8—C(═O)—R5、—NR8—C(═O)—OR4、—NR8—C(═O)—NR6R7、—NR8—C(═O)—C1-6烷基-C(═O)—OR4、—NR8—C1-6烷基-OR4、—NR8—C1-6烷基-NR6R7、—NR8—C1-6烷基-咪唑基、—NR8—SO2R9、—N═CH—NR6R7、—NH—C(═NH)—NH2、—SO2NR6R7和—O—PO(OR8)2;D为吡啶嘧啶吡嗪吡嗪二氮杂环、吡咯咪唑吡唑呋喃噁唑异噁唑噻吩噻唑异噻唑;R2为C1-C6烷基、多卤C1-C6烷基、卤素、基、—COOR4、—OR4和—NR6R7;R3为苯基、吡啶基、嘧啶基、咪唑吡啶基、吡唑吡啶基、三唑吡啶基、喹啉咪唑嘧啶基、吡唑嘧啶基、三唑嘧啶基、吡啶嘧啶基;这些基团可以选择性地被取代;m为0、1、2或3;n为0、1、2或3;含有这些化合物的药物组合物,制备这些化合物和组合物的方法。
  • HIV INHIBITING 3,4-DIHYDRO-IMIDAZOÝ4,5-B¨PYRIDIN-5-ONES
    申请人:Tibotec Pharmaceuticals Ltd.
    公开号:EP2004647A1
    公开(公告)日:2008-12-24
  • US7994187B2
    申请人:——
    公开号:US7994187B2
    公开(公告)日:2011-08-09
  • [EN] HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES<br/>[FR] 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES INHIBANT LE VIH
    申请人:TIBOTEC PHARM LTD
    公开号:WO2007113290A1
    公开(公告)日:2007-10-11
    [EN] HIV inhibitory compounds of formula (I) salts, hydrates, solvates, N-oxides, or stereoisomers thereof, wherein A forms pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, and thiadiazole; R1 is halo, cyano, nitro, C1-6alkyl, polyhaloC1-6alkyl, -C1-6alkyl-OR4, -C(=O)-R5, -C(=O)-OR4, -C(=O)-NR6R7, -OR4, -O-C(=O)-C1-6alkyl, -O-C1-6alkyl-OR4, -O-C1-6alkyl-NR6R7, -O-C1-6alkyl-O-C(=O)-C1-6Alkyl, -O-C1-6alkyl-C(=O)-OR4, -O-C1-6alkyl-C(=O)-NR6R7, -NR6R7, -NR8-C(=O)-R5, -NR8-C(=O)-OR4, -NR8-C(=O)-NR6R7, -NR8-C(=O)-C1-6lkyl-C(=O)-OR4, -NR8-C1-6alkyl-OR4, -NR8-C1-6alkyl-NR6R7, -NR8-C1-6alkyl-imidazo lyl, -NR8-SO2R9, -N=CH-NR6R7, -NH-C(=NH)-NH2, -SO2NR6R7, and -O-PO(OR8)2; D forms pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophene, thiazole, and isothiazole; R2 is C1-6alkyl, polyhaloC1-6alkyl, halo, cyano, -COOR4, -OR4, and -NR6R7; R3 is phenyl, pyridyl, pyrimidinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, quinoline, imidazopyrimidinyl, pyrazolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl; which may optionally be substituted; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; 25 pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.
    [FR] L'invention concerne des composés inhibant le VIH et répondant à la formule (I), et des sels, hydrates, solvates, N-oxydes, ou stéréoisomères desdits composés. A représente des groupes pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tétrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, et thiadiazole ; R1 représente un atome d'halogène, des groupes cyano, nitro, alkyle en C1 à C6, polyhalogéno(alkyle en C1 à C6), -(alkyle en C1 à C6)-OR4, -C(=O)-R5, -C(=O)-OR4, -C(=O)-NR6R7, -OR4, -O-C(=O)-(alkyle en C1 à C6), -O-(alkyle en C1 à C6)-OR4, -O-(alkyle en C1 à C6)-NR6R7, -O-(alkyle en C1 à C6)-O-C(=O)-(alkyle en C1 à C6), -O-(alkyle en C1 à C6)-C(=O)-OR4, -O-(alkyle en C1 à C6)-C(=O)-NR6R7, -NR6R7, -NR8-C(=O)-R5, -NR8-C(=O)-OR4, -NR8-C(=O)-NR6R7, -NR8-C(=O)-(alkyle en C1 à C6)-C(=O)-OR4, -NR8-(alkyle en C1 à C6)-OR4, -NR8-(alkyle en C1 à C6)-NR6R7, -NR8-(alkyle en C1 à C6)-imidazolyle, -NR8-SO2R9, -N=CH-NR6R7, -NH-C(=NH)-NH2, -SO2NR6R7, et -O-PO(OR8)2 ; D représente des groupes pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophène, thiazole, et isothiazole ; R2 représente un groupe alkyle en C1 à C6, un groupe polyhalogéno(alkyle en C1 à C6), un atome d'halogène, des groupes cyano, -COOR4, -OR4, et -NR6R7 ; R3 représente des groupes phényle, pyridyle, pyrimidinyle, imidazopyridyle, pyrazolopyridyle, triazolopyridyle, quinoléine, imidazopyrimidinyle, pyrazolopyrimidinyle, triazolopyrimidinyle, pyridopyrimidinyle ; lesdits groupes pouvant éventuellement être substitués ; m vaut 0, 1, 2 ou 3 ; n vaut 0, 1, 2 ou 3 ; l'invention concerne également des compositions pharmaceutiques contenant ces composés, des procédés de préparation de ces composés et des compositions.
查看更多